for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SanBio Co Ltd

4592.T

Latest Trade

4,205.00JPY

Change

50.00(+1.20%)

Volume

322,800

Today's Range

4,135.00

 - 

4,235.00

52 Week Range

2,401.00

 - 

12,730.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4,155.00
Open
4,195.00
Volume
322,800
3M AVG Volume
16.67
Today's High
4,235.00
Today's Low
4,135.00
52 Week High
12,730.00
52 Week Low
2,401.00
Shares Out (MIL)
51.78
Market Cap (MIL)
215,166.80
Forward P/E
-39.12
Dividend (Yield %)
--

Next Event

Q3 2019 SanBio Co Ltd Earnings Release

Latest Developments

More

SanBio Says U.S. FDA Granted Regenerative Medicine Advanced Therapy Designation For SB623

SanBio says exercise of options

SanBio says exercise of options

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SanBio Co Ltd

SanBio Company Limited is a Japan-based company primarily engaged in the research and development of regenerative cells drugs. The Company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

Industry

Biotechnology & Drugs

Contact Info

28F, St. Luke Tower, 8-1, Akashi-cho

+81.3.62643481

http://www.sanbio.jp/

Executive Leadership

Toru Kawanishi

Chairman of the Board, Executive Officer, Representative Director

Keita Mori

President, Executive Officer, Chairman of Subsidiary, Representative Director

Akihiro Tsujimura

Senior Managing Director, Executive Officer, Chief Executive Officer of Subsidiary

Yoshihiro Sumiya

Executive Officer, Director of Business Administration

Hiroshi Yamamoto

Executive Officer, Director of Business

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (JPY)

2017

-40.880

2018

-86.850

2019

-60.170

2020(E)

-106.198
Price To Earnings (TTM)
--
Price To Sales (TTM)
285.45
Price To Book (MRQ)
15.50
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
28.84
LT Debt To Equity (MRQ)
28.84
Return on Investment (TTM)
-25.03
Return on Equity (TTM)
-23.71

Latest News

Latest News

SanBio's crash causes margin calls, drags down Japan's start-up market

A crash by a Tokyo biopharmaceutical firm's shares on Wednesday ended a month-long rally in Japan's start-up market that was fueled by retail investors feeling small-cap stocks could rise despite global economic risks.

BRIEF-SanBio announces exercise of options

* Says 4,000 units of its 13th series options were exercised to 400,000 shares of its common stock from April 9 to April 10

BRIEF-SanBio and Teijin to terminate licensing agreement regarding SB623 for stroke treatment

* Says co and Teijin Limited would terminate the exclusive licensing agreement signed in 2009, regarding the development and marketing of SB623 for stroke treatment in Japan

BRIEF-SanBio and unit receive subsidy of $4.5 mln from CIRM

* Says it and unit SanBio, Inc., received subsidy of $4.5 million from CIRM, for chronic cerebral infarction related clinical trials, on Jan. 26 (the U.S. time)

BRIEF-SanBio and unit receives subsidy of $4.1 mln from CIRM

* Says it and unit, SanBio, Inc., received subsidy of $4.1 million from CIRM, on Dec. 13 (the U.S. time)

BRIEF-SanBio signs commitment line agreement worth 1.6 bln yen

* Says it signs a commitment line agreement worth 1.6 billion yen on Aug. 21, with a term from Aug. 21 to July 31, 2021

BRIEF- SanBio receives $20 mln subsidy

* Says it received $20 million subsidy from California Institute for Regenerative Medicine (CIRM), for cerebral infarction phase 2b clinical study

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up